UK medical cannabis registry: an updated analysis of clinical outcomes of cannabis-based medicinal products for inflammatory bowel disease
CBMP treatment was associated with improvement in IBD-specific outcomes in patients and general HRQoL over 18-months. However, causation cannot be inferred. Hence, randomized controlled trials are still required.
Authors
- Aashray Gupta (ORCID: https://orcid.org/0000-0002-8038-0378)
- Ross Coomber (ORCID: https://orcid.org/0000-0002-8144-1996)
- Lara Bapir
- Monica Kelada (ORCID: https://orcid.org/0000-0002-0993-901X)
- Simon Erridge (ORCID: https://orcid.org/0000-0001-5871-6501)
- James Rucker (ORCID: https://orcid.org/0000-0003-4647-8088)
- Vivian Graf
- Kaitlyn McLachlan (ORCID: https://orcid.org/0000-0003-4569-7529)
- Mikael H. Sodergren (ORCID: https://orcid.org/0000-0002-7141-3924)
- Michael Platt
- Eleanor Clarke (ORCID: https://orcid.org/0000-0002-2150-2283)
- John Warner‐Levy (ORCID: https://orcid.org/0000-0003-2632-7266)
- Naveen Jesuraj
Institutions
- St George's Hospital (GB)
- King's College London (GB)
- South London and Maudsley NHS Foundation Trust (GB)
- St George's Hospital (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Expert Review of Gastroenterology & Hepatology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1080/17474124.2024.2443574
- Citations
- 3
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 1.34